TNFRSF8/CD30 Antibody - CD BioSciences

service-banner

TNFRSF8/CD30 Antibody

TNFRSF8/CD30 Antibody

SPA-10983

Size Price
100 µg Online Inquiry
25 µg Online Inquiry
More Options Online Inquiry
Target Information
Target Name TNF receptor
Gene Abbr. TNFRSF8
Gene ID 943
Full Name TNF receptor superfamily member 8
Alias CD30, D1S166E, Ki-1
Introduction TNFRSF8/CD30 is a type-I transmembrane glycoprotein that is a member of the TNFR superfamily. CD30 is synthesized as a precursor protein that undergoes extensive posttranslational modification before becoming embedded in the plasma membrane as a 120-kDa transmembrane protein. The expression of CD30 is upregulated in activated T-cells and may trigger costimulatory signaling pathways upon its engagement. While its expression is normally restricted to subsets of activated T-cells and B-cells, CD30 expression is robustly upregulated in hematologic malignancies, such as Hodgkin’s lymphoma anaplastic large cell lymphoma (ALCL), and adult T-cell leukemia, thus making it an attractive target for therapeutic intervention. Research studies have suggested that in certain disease contexts, CD30 recruits TRAF2 and TRAF5 adaptor proteins to drive NF-kappa B activation, aberrant cell growth, and cytokine production. CD30 signaling is also regulated by TACE-dependent proteolytic cleavage of its ectodomain, which results in reduced CD30L-dependent activation of CD30+ cells.
Product Details
Host Mouse
Clonality Monoclonal
Clone No. Ki-1/779
Isotype IgG1 Kappa
Immunogen Recombinant human TNFRSF8 protein.
Usage
Application FC, IHC, IF
Dilutions Flow Cytometry (0.5-1 µg/10^6 cells in 0.1 mL); Immunofluorescence (1-2 µg/mL)
Reactivity Human
Specificity Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkins disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).
Storage & Handling
Storage Buffer 10 mM PBS with 0.05% BSA.
Preservative 0.05% Sodium Azide
Storage Temp. Store at 4 °C.

For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.